GL1X · GenesisL1 explorer

Research workbench

Identification of a glycogen synthase kinase-3B inhibitor that attenuates hyperactivity in clock mutant mice

Analyse Identification of a glycogen synthase kinase-3B inhibitor that attenuates… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3SD0
Type
protein
Length
699 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Glycogen synthase kinase-3 beta
EC
2.7.11.26
UniProt
P49841
Ligands
TSK
Pockets
8 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 35% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGlycogen synthase kinase-3 beta (EC 2.7.11.26)protein35034% helix, 19% strandP49841
BGlycogen synthase kinase-3 beta (EC 2.7.11.26)protein34936% helix, 18% strandP49841

Ligands and binding sites

  • TSK · 3-(5-fluoro-6-iodo-1-methyl-1H-indol-3-yl)-4-(7-methoxy-1-benzofuran-3-yl)-1H-pyrrole-2,5-dione · ligand · 2 copies · chains A, B
  • EPE · 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110570.800.8281TSK, EPE
211070.800.8183TSK, EPE
3890.760.9831empty
41040.460.7923empty
51610.450.7530empty

Interfaces

1 interface between chains.

  • A–B · 1503 Ų buried · 15 hydrogen bonds · protein-protein

Compared structures

  • 3SD0 · Identification of a Glycogen Synthase Kinase-3b Inhibitor that Attenuates Hyperactivity… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.